Dr. Katie S. Murray, DO on Evolving Treatment Strategies for NMIBC
Dr. Katie Murray discusses the diagnosis and management of non–muscle invasive bladder cancer, emphasizing cystoscopy and initial TURBT as the standard for accurate diagnosis and...
Urothelial Carcinoma
Latest Posts
Phase III KEYNOTE-B15: Perioperative Enfortumab Vedotin-ejfv + Pembrolizumab Improves Outcomes in Cisplatin-Eligible Muscle-Invasive Bladder Cancer
Phase III KEYNOTE-B15 data demonstrate significant improvements in event-free survival (EFS), overall survival (OS) and...
ANKTIVA® Plus BCG Demonstrates Durable Response, Bladder Preservation, and 96% Survival in BCG-Unresponsive Papillary NMIBC
This article reviews long-term outcomes of the IL-15 receptor agonist nogapendekin alfa inbakicept (NAI) combined...
A New Era in MIBC: Perioperative Pembrolizumab + Enfortumab Vedotin Approved for Cisplatin-Ineligible Patients
On November 21, 2025, the U.S. Food and Drug Administration approved pembrolizumab (Keytruda or Keytruda...
Prospective DRIVE Study Demonstrates Strong Diagnostic Performance of CxBladder Triage Plus in Hematuria Evaluation
The CxBladder Triage Plus DRIVE study showed high accuracy in detecting urothelial carcinoma in patients...
New CMS J-Code Set to Enhance Adoption of Mitomycin Therapy for Recurrent LG-IR-NMIBC
CMS has assigned a permanent J-code (J9282) to ZUSDURI, an intravesical mitomycin therapy for recurrent...
IMvigor011: Signatera™ ctDNA Testing Guides Adjuvant Atezolizumab Benefit in Muscle-Invasive Bladder Cancer
Signatera-positive patients treated with atezolizumab had statistically significant improvements in disease-free and overall survival.
KEYNOTE-905: First Perioperative Therapy to Demonstrate Survival Benefit in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
First positive Phase 3 trial shows perioperative immunotherapy combination addresses critical gap for cisplatin-ineligible patients.
Sasanlimab-BCG Combination Achieves 32% Risk Reduction in BCG-Naïve High-Risk NMIBC: Phase 3 CREST Trial Results
32% risk reduction in high-risk bladder cancer with sasanlimab-BCG combo—first treatment advance in 30+ years...
FDA Approves Gemcitabine Intravesical System (Inlexzo) for BCG-Unresponsive Bladder Cancer
FDA approves gemcitabine intravesical system for BCG-unresponsive bladder cancer, showing 82% complete response rate in...
TAR-200 Achieves 82% Complete Response in BCG-Refractory Bladder Cancer: SunRISe-1 Results
New drug-releasing system, TAR-200, eliminated tumors in 82% of patients in phase 2 clinical trial...
Economic Analysis: Trimodal Therapy vs Radical Cystectomy Cost-Effectiveness in Muscle-Invasive Bladder Cancer
TMT was not cost-effective at 5-year (ICER, $464,291 per QALY) or 10-year (ICER, $308,638 per...
Phase III IMvigor011 Trial Validates ctDNA-Guided Adjuvant Immunotherapy in Bladder Cancer
IMvigor011 trial shows Signatera ctDNA test predicts which bladder cancer patients benefit from adjuvant atezolizumab...
SOGUG-AUREA Trial: Split-Dose Cisplatin Plus Atezolizumab in Urothelial Carcinoma
Split-dose cisplatin + atezolizumab achieved 48.5% response rate in cisplatin-ineligible urothelial carcinoma patients with manageable...
KEYTRUDA plus Padcev Significantly Improved Event-Free and Overall Survival and Pathologic Complete Response Rate for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
First systemic therapy to improve survival when used before/after surgery for MIBC patients ineligible for...
Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-Grade Non–Muscle-Invasive Bladder Cancer
XBCM urinary biomarker reduces cystoscopies by 55% in high-grade NMIBC surveillance without compromising recurrence detection...
Bladder Cancer at a Crossroads: Sequencing, Biomarkers, and Combination Therapy
Multiple new NMIBC therapies offer bladder preservation hope: cretostimogene shows 46% 1-year response with minimal...
FDA Approves Mitomycin Intravesical Solution for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
FDA approves mitomycin (Zusduri) for recurrent low-grade NMIBC: 78% complete response, 79% maintain response ≥12...
Expert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer
CR rates greater than 80% achieved with TAR-200 device - first time we've seen rates...
Urinary Biomarker Test XBCM Reduces Cystoscopy in High-Grade NMIBC Surveillance
XBCM urinary biomarker test achieves 91% sensitivity and 99% NPV while reducing cystoscopy burden by...
